MX360245B - Composiciones que comprenden inmunoglobulinas de tipo secretor. - Google Patents

Composiciones que comprenden inmunoglobulinas de tipo secretor.

Info

Publication number
MX360245B
MX360245B MX2014010754A MX2014010754A MX360245B MX 360245 B MX360245 B MX 360245B MX 2014010754 A MX2014010754 A MX 2014010754A MX 2014010754 A MX2014010754 A MX 2014010754A MX 360245 B MX360245 B MX 360245B
Authority
MX
Mexico
Prior art keywords
secretory
compositions
immunoglobulins
methods
iga
Prior art date
Application number
MX2014010754A
Other languages
English (en)
Other versions
MX2014010754A (es
Inventor
Zuercher Adrian
Corthésy Blaise
Longet Stéphanie
Loetscher Marius
Miescher Sylvia
Original Assignee
Csl Behring Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20120158931 external-priority patent/EP2636682A1/en
Application filed by Csl Behring Ag filed Critical Csl Behring Ag
Publication of MX2014010754A publication Critical patent/MX2014010754A/es
Publication of MX360245B publication Critical patent/MX360245B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a un método para producir una composición que comprende IgA y/o IgM de tipo secretor in vitro, caracterizado porque comprende el paso: a) mezclar una composición de proteína derivada de la sangre que tiene menos de 80% de inmunoglobulina que porta la cadena J con el componente secretor; en donde dicha IgA y/o IgM de tipo secretor tiene características funcionales y bioquímicas similares a IgA y/o IgM secretoras derivadas de mucosa.
MX2014010754A 2012-03-09 2013-03-08 Composiciones que comprenden inmunoglobulinas de tipo secretor. MX360245B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20120158931 EP2636682A1 (en) 2012-03-09 2012-03-09 Compositions comprising secretory-like immunoglobulins
EP12168343 2012-05-16
PCT/EP2013/054697 WO2013132052A1 (en) 2012-03-09 2013-03-08 Compositions comprising secretory - like immunoglobulins

Publications (2)

Publication Number Publication Date
MX2014010754A MX2014010754A (es) 2014-12-05
MX360245B true MX360245B (es) 2018-10-26

Family

ID=47846003

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010754A MX360245B (es) 2012-03-09 2013-03-08 Composiciones que comprenden inmunoglobulinas de tipo secretor.

Country Status (17)

Country Link
US (3) US10221233B2 (es)
EP (1) EP2822967B1 (es)
JP (3) JP2015510875A (es)
KR (1) KR102142261B1 (es)
CN (2) CN104254542A (es)
AU (1) AU2013201393B2 (es)
BR (1) BR112014022240A2 (es)
CA (1) CA2866634C (es)
DK (1) DK2822967T3 (es)
ES (1) ES2751976T3 (es)
IL (1) IL234449B (es)
MX (1) MX360245B (es)
NZ (1) NZ629072A (es)
PL (1) PL2822967T3 (es)
RU (1) RU2644240C2 (es)
SG (1) SG11201404958SA (es)
WO (1) WO2013132052A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2636684A1 (en) * 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
MX360245B (es) * 2012-03-09 2018-10-26 Csl Behring Ag Composiciones que comprenden inmunoglobulinas de tipo secretor.
US9458230B2 (en) 2013-01-04 2016-10-04 Wisconsin Alumni Research Foundation Secretory IGA compositions, methods of making and methods of use thereof
US9468674B2 (en) * 2013-09-24 2016-10-18 Wisconsin Alumni Research Foundation Methods of use of secretory IgA
RU2729546C2 (ru) 2014-04-03 2020-08-07 Цсл Беринг Аг Распыление иммуноглобулина
RU2599029C1 (ru) * 2015-07-16 2016-10-10 Игорь Геннадьевич Ковшик Химерный иммуноглобулиновый препарат, обладающий специфическим противовирусным или антибактериальным действием
PL3429622T3 (pl) 2016-03-14 2021-11-02 Biotest Ag Leczenie ciężkiego pozaszpitalnego zapalenia płuc
EP3558362A1 (en) 2016-12-20 2019-10-30 CSL Behring AG Methods for affecting salmonella infections
BR112020005742A2 (pt) 2017-09-21 2020-10-13 Umc Utrecht Holding B.V. anticorpo anti-gd2 para o tratamento de neuroblastoma
CN110724176B (zh) * 2018-07-16 2021-10-26 北京豪思生物科技有限公司 一种治疗阿尔茨海默症的血浆蛋白分离物及其制备方法和应用
EP3886902A1 (en) 2018-11-30 2021-10-06 CSL Behring AG Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin
CN114096559B (zh) 2019-03-27 2026-03-20 蒂嘉特克斯公司 工程化iga抗体及其使用方法
US12612467B2 (en) * 2022-09-21 2026-04-28 Michael R. Simon Treatment of necrotizing enterocolitis with semisynthetic polyclonal human secretory immunoglobin A
WO2024151506A1 (en) * 2023-01-13 2024-07-18 Simon Michael R Process for preparation of secretory iga and secretory igm and use thereof for treating necrotizing enterocolitis

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU745523A1 (ru) * 1978-06-15 1980-07-05 Всесоюзный научно-исследовательский институт гриппа Способ профилактики и лечени острых респираторных заболеваний вирусной этиологии
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US5500345A (en) 1989-04-25 1996-03-19 Iatron Laboratories, Inc. Hybridomas producing monoclonal antibodies specific for C-reactive protein and methods for detection of C-reactive protein
DE3927111C3 (de) 1989-08-17 1994-09-01 Biotest Pharma Gmbh Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate
US5258177A (en) 1991-12-10 1993-11-02 Alpha Therapeutic Corporation IgA preparation and process of making the same
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
WO1995004081A1 (en) 1993-07-30 1995-02-09 Oravax, Inc. MONOCLONAL IgA ANTIBODY AGAINST RESPIRATORY SYNCYTIAL VIRUS
NZ291659A (en) 1994-09-06 2001-04-27 Galagen Inc Use in the manufacture of a medicament of an antibody having specific activity against Clostridium difficile, and pharmaceutical compositions comprising Anti-Clostridium difficile bovine immunoglobulin concentrate; for treating diseases associated with Clostridium difficile
DE19600939C1 (de) 1996-01-12 1997-08-28 Immuno Ag Verfahren zur Trennung von IgG und IgA
EP0839915A1 (en) * 1996-11-01 1998-05-06 Institut Suisse De Recherches Experimentales Sur Le Cancer Isrec Secretory immunoglobulin A as a mucosal vaccine delivery system
US6300104B1 (en) 1997-06-19 2001-10-09 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US20020114802A1 (en) * 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
IL140155A (en) 1998-06-09 2005-12-18 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
JP2000103800A (ja) 1998-09-29 2000-04-11 Yoshitomi Pharmaceut Ind Ltd 免疫グロブリンａの精製方法
AUPP806999A0 (en) 1999-01-08 1999-02-04 Csl Limited Process for purifying immunoglobulins
EP1068871A1 (en) 1999-07-07 2001-01-17 Jean-Paul Perraudin Novel methods and medicament for treating infections diseases involving microbial biofilms
US6974573B2 (en) 1999-11-01 2005-12-13 Mucovax Holdings, B.V. Antibody production in farm animals
ES2292493T3 (es) 1999-12-13 2008-03-16 Universidad Nacional Autonoma De Mexico Metodo inmunoenzimatico de cuantificacion.
US6696620B2 (en) 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
NZ527977A (en) 2001-02-12 2005-10-28 Medarex Inc Human monoclonal antibodies to FC alpha receptor (CD89)
US6932967B2 (en) 2001-03-22 2005-08-23 Michael R. Simon Human medical treatment by aerosol inhalation of immunoglobulin A
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
US20060165675A1 (en) 2002-08-02 2006-07-27 Richman-Eisenstat Janice Beth Modulation of mesenchymal cells via iga-receptors
WO2005047337A1 (en) 2003-11-13 2005-05-26 Hanmi Pharmaceutical Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
US8709413B2 (en) 2006-12-13 2014-04-29 Michael R. Simon Treatment of celiac disease with IgA
US8119104B2 (en) 2006-12-13 2012-02-21 Michael R. Simon Treatment of celiac disease with IgA
US20080145420A1 (en) 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
US8313730B2 (en) 2006-12-13 2012-11-20 Michael R. Simon Treatment of celiac disease with IgA
US8021645B2 (en) 2006-12-13 2011-09-20 Simon Michael R Synthesis of human secretory IgA and IgM and the formation of a medicament therefrom
US7794721B2 (en) * 2006-12-13 2010-09-14 Simon Michael R Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
US7597891B2 (en) * 2006-12-13 2009-10-06 Simon Michael R Synthesis of human secretory IgA for the treatment of Clostridium difficile associated diseases
EP2244735A4 (en) 2007-10-02 2011-02-23 Avaxia Biologics Inc ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE
JP5762951B2 (ja) * 2008-05-15 2015-08-12 ダブリュ．・ヘルス・エル．ピー．Ｗ． Ｈｅａｌｔｈ Ｌ．Ｐ． 分泌性免疫グロブリンの豊富な乳画分の製造方法
GB201006753D0 (en) * 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
JP5753998B2 (ja) 2010-11-02 2015-07-22 国立大学法人三重大学 ウレタン硬化性組成物、その硬化体、キットおよび硬化体の製造方法
EP2465536A1 (en) 2010-12-14 2012-06-20 CSL Behring AG CD89 activation in therapy
BR112014004162A2 (pt) 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
CN104136121B (zh) 2012-02-14 2017-04-19 生物辐射实验室股份有限公司 减少离子交换色谱中的pH漂移
EP2636683A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Treatment of mucositis with Immunoglobulin
EP2636684A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
MX360245B (es) * 2012-03-09 2018-10-26 Csl Behring Ag Composiciones que comprenden inmunoglobulinas de tipo secretor.
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species

Also Published As

Publication number Publication date
JP2015510875A (ja) 2015-04-13
JP2021038246A (ja) 2021-03-11
US10385117B2 (en) 2019-08-20
KR20140132770A (ko) 2014-11-18
CN104254542A (zh) 2014-12-31
US20140371431A1 (en) 2014-12-18
KR102142261B1 (ko) 2020-08-11
US20190256577A1 (en) 2019-08-22
JP7575920B2 (ja) 2024-10-30
CA2866634C (en) 2022-07-19
RU2014140744A (ru) 2016-04-27
US11623948B2 (en) 2023-04-11
AU2013201393B2 (en) 2015-08-27
EP2822967A1 (en) 2015-01-14
AU2013201393A1 (en) 2013-09-26
CN111116735A (zh) 2020-05-08
NZ629072A (en) 2016-03-31
EP2822967B1 (en) 2019-08-07
WO2013132052A1 (en) 2013-09-12
HK1204628A1 (en) 2015-11-27
SG11201404958SA (en) 2014-11-27
PL2822967T3 (pl) 2020-01-31
IL234449B (en) 2018-07-31
MX2014010754A (es) 2014-12-05
US10221233B2 (en) 2019-03-05
US20150056180A1 (en) 2015-02-26
BR112014022240A2 (pt) 2017-08-01
JP2019038834A (ja) 2019-03-14
DK2822967T3 (da) 2019-10-07
RU2644240C2 (ru) 2018-02-08
US20170058018A2 (en) 2017-03-02
CA2866634A1 (en) 2013-09-12
ES2751976T3 (es) 2020-04-02

Similar Documents

Publication Publication Date Title
MX2014010754A (es) Composiciones que comprenden inmunoglobulinas de tipo secretor.
IL281731A (en) Humanized antibodies that recognize alpha-synuclein, preparations containing them and their uses
IL272615B (en) Humanized antibodies that recognize alpha-synuclein, preparations containing them and their uses
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
PH12014502406B1 (en) Anti-il-23p19 antibodies
IL236348A0 (en) Anti-Jagad antibodies, preparations containing them and their uses
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
IL237625A0 (en) Antibodies against m-cam, preparations containing them and their uses
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
WO2014078866A3 (en) Engineered immunoglobulins with extended in vivo half-life
IL235004A0 (en) Antibodies against fgfr2, preparations containing them and their uses
HK1218549A1 (zh) 新型抗体框架
HK1207654A1 (en) Modified antibody regions and uses thereof
SI2849723T1 (sl) Formulacije z visoko koncentracijo monoklonskih protiteles
WO2014078268A8 (en) Anti-hemagglutinin antibodies and methods of use
EA201590173A1 (ru) Иммуноконъюгаты, содержащие антитела к cd22
WO2013063613A3 (en) Methods and compositions related to intracellular neutralization by igg
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
WO2012109238A3 (en) Methods for increasing immune responses using agents that directly bind to and activate ire-1
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
MX2014000531A (es) Metodos y composiciones para el tratamiento del asma usando anticuerpos anti-il-13.
EP3510046A4 (en) ANTIBODIES AGAINST OXIDATION-SPECIFIC EPITOPES
WO2014091167A3 (fr) Composes cyclopropylboroniques, leur procede de preparation et leur utilisation
HUE049860T2 (hu) IL-ß-t neutralizáló, humán monoklonális antitestek

Legal Events

Date Code Title Description
FG Grant or registration